glp-1 and gip hormones Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art GIP and GLP‐1, the two

This slowing effect occurs through several mechanisms: GLP-1 reduces gastric motility, decreases the force of stomach contractions, and influences the pyloric sphincter (the valve between the stomach and small intestine)

Strategic use cases: Matching the tool to the goal The right approach depends entirely on the individuals specific health profile and goals

What should people know

This ensures your progress is on track, your dosing is appropriate, and your treatment remains safe and effective

A new post hoc analysis of SURMOUNT confirms psychiatric safety of Tirzepatide Published in Obesity journal (Jan 2026), this study pooled data from SURMOUNT-1, -2, and -3 trials (4,056 participants)

Progress will depend on biomarker-driven, biologically enriched trial designs capable of determining whether the pleiotropic benefits observed in experimental systems translate into meaningful disease modification